bioAffinity shares surge 15.32% intraday as CyPath® Lung clinical study demonstrates 92% sensitivity for small nodules and 2025 earnings report shows 87% sales growth for flagship test.

bioAffinity surged 15.32% intraday, driven by the release of a clinical case study showcasing its CyPath® Lung test's 92% sensitivity and 87% specificity for detecting non-malignant lung nodules in high-risk patients, and Q1 2025 financial results reporting an 87% year-over-year sales growth for the flagship product, which propelled annual testing volume to increase by 99%.